XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
January 04 2021 - 4:05PM
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive
Officer, Jim Neal, will present at two upcoming investor
conferences:
- H.C. Wainwright Virtual BioConnect 2021 Conference taking place
January 11-14, 2021. XOMA’s presentation will be available on
demand beginning January 11, 2021 at 6:00 AM ET and can be accessed
at http://bit.ly/3hFUIaA.
- Biotech Showcase Digital Conference taking place January 11-15,
2021. The Company’s presentation will be available to
registered participants.
The presentations can also be accessed by visiting
the investor relations section of the Company’s website at
www.xoma.com. Replays of the presentations will be available
and archived on the site for 90 days after the event.
About XOMA CorporationXOMA has
built a significant portfolio of products that are licensed to and
being developed by other biotechnology and pharmaceutical
companies. The Company’s portfolio of partner-funded programs
spans multiple stages of the drug development process and across
various therapeutic areas. Many of these licenses are the
result of XOMA’s pioneering efforts in the discovery and
development of antibody therapeutics. The Company’s
royalty-aggregator business model includes acquiring additional
licenses to programs with third-party funding. For more
information, visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
creating additional value for the stockholders and cash sufficiency
forecast. These statements are based on assumptions that may
not prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry, including those related to the fact that
our product candidates subject to out-license agreements are still
being developed, and our licensees may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; if
the therapeutic product candidates to which we have a royalty
interest do not receive regulatory approval, our third-party
licensees will not be able to market them. Other potential
risks to XOMA meeting these expectations are described in more
detail in XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering
XOMA's prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward-looking statement, except as required by
applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in
this press release refer strictly to milestone and/or royalty
rights associated with a basket of drug products in
development. Any references to “assets” in this press release
refer strictly to milestone and/or royalty rights associated with
individual drug products in development. References to
royalties or royalty rates strictly refer to future potential
payment streams regardless of whether or not they are technically
defined as royalties in the underlying contractual agreement;
further, any rates referenced herein are subject to potential
future contractual adjustments.
As of the date of this press release, all assets in
XOMA’s milestone and royalty portfolio are investigational
compounds. Efficacy and safety have not been
established. There is no guarantee that any of these assets
will become commercially available.
Investor contact:Juliane
SnowdenOratorium Group, LLC+1
646-438-9754jsnowden@oratoriumgroup.com
Media contact:Kathy VincentKV
Consulting & Management+1
310-403-8951kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024